<DOC>
	<DOCNO>NCT00115583</DOCNO>
	<brief_summary>The purpose study assess importance substance call endothelin . Endothelin produce coronary artery . This study examine substance determine whether effect control blood flow coronary artery . When arteries release much endothelin , blood flow heart muscle reduce may important heart condition . This protocol examine investigational drug call BQ-123 see block effect endothelin . We assess blood flow coronary evaluate effect BQ-123 . It anticipate endothelin blocker open coronary artery increase blood flow heart .</brief_summary>
	<brief_title>The Contribution Endothelin Vasomotor Function Diseased Coronary Arteries</brief_title>
	<detailed_description>There many substance influence diameter coronary artery number actually release lining coronary artery ( referred endothelium ) . Over past 15 year , laboratory instrumental establish role endothelium-released relaxing factor relax ( open ) coronary artery . We focus attention factor constrict coronary artery , particular substance call endothelin-1 ( ET-1 ) . This potent constrictor substance find accumulate coronary artery site may produce unstable angina ( ie culprit lesion stenosis ) . Hence ET-1 may produce localized constriction coronary stenosis thereby narrow remain lumen cut blood flow heart muscle thus lead unstable angina . If ET-1 important development unstable angina , medication inhibit effect ET-1 improve condition . To achieve blockade ET-1 , inhibitor two receptor ( ET-A ET-B ) responsible ET-1 's action must administer . Animal human study demonstrate blockade ET-A receptor new antagonist , BQ-123 , inhibit ET-1 induced constrictor response . BQ-123 safely administer systemically intravenous infusion locally human forearm produce dilation forearm artery . It previously administer human coronary artery . Consented patient whose routine diagnostic angiogram show suitable anatomy ( i.e. , normal angiogram control group , one/two vessel coronary artery disease identifiable culprit stenosis ) placement coronary artery angiographic catheter . Placement catheter require additional puncture artery ( already perform routine diagnostic angiogram ) . The angiographic catheter allow visualization internal diameter coronary artery injection radiographic contrast image record cine film . Specialized image machine measure diameter vessel . Through angiographic catheter , infusion catheter ( drug administer ) coronary Doppler flow wire place coronary artery . The latter instrument well-established tool measure coronary blood flow . After establish baseline value heart rate , blood pressure , culprit stenosis internal diameter coronary blood flow , follow sequential intracoronary infusion undertake : 1 . Infusion endothelin antagonist , BQ-123 , 60 minute period . This inhibitor require 60 minute exert full effect ; 2 . Adenosine bolus injection , assess vasodilation capacity small coronary artery ; 3 . Nitroglycerin bolus injection , ass maximal vasodilation capacity large coronary artery . At 5 , 15 , 30 , 45 , 60 minute endothelin antagonist infusion , immediately bolus injection , parameter reassess . It anticipate research protocol complete within 90 minute . Following research protocol , patient undergo appropriate coronary intervention dictate clinical situation . If coronary atherectomy require clinical indication , specimen extract procedure send specific analysis endothelin-1 content . A correlation amount endothelin culprit stenosis response endothelin antagonist examine . In cardiac transplant recipient , endomyocardial biopsy also routinely obtained clinical purpose time catheterization . One specimens use ET-1 immunoreactivity analysis . A total 2 teaspoon blood take frozen analysis .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>Adult men woman age 18 75 year enrol categorize one 4 group . The category define : Control patient characterize chest pain angiographically normal coronary artery . Chronic stable angina patient describe history exertional chest pain unchanged frequency precede month , least 70 % stenosis coronary artery . Unstable angina patient describe chest pain rest minimal exertion precede 2 week , identifiable culprit stenosis coronary artery . Cardiac transplant recipient undergo routine annual surveillance cardiac catheterization . Patients follow exclude study : Angiographic exclusion criterion : *Left main coronary artery disease severe triple vessel disease ; *Unstable angina without identifiable culprit lesion . Severe leave ventricular dysfunction ( ejection fraction &lt; 40 % ) clinical cardiac failure . Nitroglycerin require precede 4 hour prior investigation . Severe renal , hepatic hematologic abnormality . Inability obtain write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>